Ultragenyx

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for DTX401, an investigational gene therapy aimed at treating Glycogen

Biopharma

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme binary outcomes, the market saw one of the most significant single-day collapses in recent history alongside a